Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (Nasdaq: TLSA), a biotechnology company, has applied for a grant from the ALS Association to fund a clinical trial for intranasal foralumab, an anti-CD3 monoclonal antibody. The grant is part of the Hoffman ALS Clinical Trial Awards Program. The trial aims to evaluate the safety, dosing, and biomarkers of foralumab in ALS patients using cutting-edge imaging techniques like PET scans. Previously, foralumab showed promising results in an Expanded Access Program for non-active secondary progressive multiple sclerosis. The company hopes the grant will support a 6-month trial involving 20 participants, advancing their efforts to develop effective ALS treatments.
Tiziana Life Sciences announced that Dr. Howard L. Weiner, its Scientific Advisory Board Chairman, will receive the 'Giants of MS' award for his contributions to multiple sclerosis (MS) research.
The award will be presented at the Consortium of Multiple Sclerosis Centers annual meeting on May 30, 2024.
Dr. Weiner is celebrated for his work on innovative treatments like intranasal foralumab, which shows promise in improving the lives of MS patients.
Foralumab has shown positive results in an Expanded Access Program, with 70% of patients experiencing improved fatigue.
The drug is also undergoing a Phase 2a trial, with data expected in 2025.
Tiziana Life Sciences, a biotechnology company, files for Orphan Drug Designation for intranasal foralumab for treating non-active secondary progressive Multiple Sclerosis, aiming to be the first therapy to receive this designation. Supported by clinical evidence, the drug has shown positive results in an Expanded Access Program, improving fatigue in 70% of patients. A Phase 2a trial is ongoing, with a data readout expected in 2025. Orphan Drug Designation brings significant benefits if approved.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
